Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 6, 2024JAAD Case ReportsOpen Access

Sclerotic chronic cutaneous graft-versus-host-disease following pseudoallogeneic chimeric antigen receptor T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEsther ChoiUniversity of British ColumbiaCNCuong V. NguyenNorthwestern University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Choi et al. (2024) studied this question.

synapsesocial.com/papers/68e612a3b6db6435875a5d1fhttps://doi.org/10.1016/j.jdcr.2024.06.014
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,114 citations
  2. 2Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia2018 · 2,752 citations
  3. 3Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults2017 · 1,158 citations
  4. 4Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia2021 · 108 citations
  5. 5Sclerodermatous Graft-vs-Host Disease2002 · 102 citations